MYC and colorectal carcinoma: Studies investigating the possibility of using lower doses of PXL for realizing more effective and safer chemotherapy include the report by Li et al. (2018)37, which revealed its downregulating effect on c-Myc and P-c-Myc expression, thereby resulting in arresting the cellular cycle in the G0/G1 phase in the colorectal carcinoma cell line HCT-116.